Effects of a combination of oral anti‐diabetes drugs with basal insulin therapy on β‐cell function and glycaemic control in patients with newly diagnosed type 2 diabetes

Abstract

In newly diagnosed type 2 diabetes, therapy with oral drugs + insulin has had favourable outcomes on recovery and maintenance of β-cell function and protracted glycaemic remission compared with treatment with oral drugs alone.

Marked recovery from glucotoxicity of β-cell function after medical nutrition therapy without pharmacotherapy in type 2 diabetic outpatients with extreme hyperglycemia: a pilot retrospective study

“…Short-term exogenous insulin administration is therefore often considered as a practical management of newly diagnosed type 2 diabetes presenting extreme hyperglycemia [2]. Indeed, numerous clinical studies have reported that β-cell dysfunction is ameliorated after temporary insulin therapy in these patients [6][7][8]. However, it remained unclear whether β-cell function can recover by its own ability, without any aid of antidiabetic pharmacotherapy.…”

Ameliorated pancreatic β cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin

“…Although the improvement of β cell function after correcting hyperglycemia is well described in animal models, evidence still remains to be well established in humans. Previous studies demonstrated that lowering plasma glucose concentrations with insulin therapy improved β cell function in diabetic patients [25][26][27][28]. However, as is well known, the β cell expresses insulin receptors; the administration of exogenous insulin potentially exerts a gly- needed to confirm whether any change smaller than 1-SD is present in insulin sensitivity.…”

Prescription patterns for diabetes mellitus and therapeutic implications: a population-based analysis

“…A retrospective study demonstrated that patients with DM type 2 treated with metformin or sulfonylurea monotherapy did not need additional treatment for 14.5 to 20.5 months, respectively, and, after these periods, glycosylated hemoglobin (HbA1c) exceeded 8.0% for both therapeutic options. DM is a progressive disease that can cause deterioration of glycemic control (glucose toxicity), making it necessary to change pharmacotherapy with time (23,24).…”

“…In the present study, 6.9% of the patients were treated with metformin and insulin (Table 1). However, recent data have shown favorable outcomes related to the recovery and maintenance of b-cell function and protracted glycemic remission in newly diagnosed patients with DM type 2, which made therapy with OAD plus insulin comparable with OAD alone (20,24).…”